Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders
Open accessThe DOI matches its Crossref record; 262 of the 262 references it cites were found in a registry or an index.
Abstract
Introduction: The initiative of a consensus on the topic of antidepressant and anxiolytic drug use in pregnancy is developing in an area of clinical uncertainty. Although many studies have been published in recent years, there is still a paucity of authoritative evidence-based indications useful for guiding the prescription of these drugs during pregnancy, and the data from the literature are complex and require expert judgment to draw clear conclusions. Methods: For the elaboration of the consensus, we have involved the scientific societies of the sector, namely, the Italian Society of Toxicology, the Italian Society of Neuropsychopharmacology, the Italian Society of Psychiatry, the Italian Society of Obstetrics and Gynecology, the Italian Society of Drug Addiction and the Italian Society of Addiction Pathology. An interdisciplinary team of experts from different medical specialties (toxicologists, pharmacologists, psychiatrists, gynecologists, neonatologists) was first established to identify the needs underlying the consensus. The team, in its definitive structure, includes all the representatives of the aforementioned scientific societies; the task of the team was the evaluation of the most accredited international literature as well as using the methodology of the “Nominal Group Technique” with the help of a systematic review of the literature and with various discussion meetings, to arrive at the drafting and final approval of the document. Results: The following five areas of investigation were identified: (1) The importance of management of anxiety and depressive disorders in pregnancy, identifying the risks associated with untreated maternal depression in pregnancy. (2) The assessment of the overall risk of malformations with the antidepressant and anxiolytic drugs used in pregnancy. (3) The evaluation of neonatal adaptation disorders in the offspring of pregnant antidepressant/anxiolytic-treated women. (4) The long-term outcome of infants’ cognitive development or behavior after in utero exposure to antidepressant/anxiolytic medicines. (5) The evaluation of pharmacological treatment of opioid-abusing pregnant women with depressive disorders. Conclusions: Considering the state of the art, it is therefore necessary in the first instance to frame the issue of pharmacological choices in pregnant women who need treatment with antidepressant and anxiolytic drugs on the basis of data currently available in the literature. Particular attention must be paid to the evaluation of the risk/benefit ratio, understood both in terms of therapeutic benefit with respect to the potential risks of the treatment on the pregnancy and on the fetal outcome, and of the comparative risk between the treatment and the absence of treatment; in the choice prescription, the specialist needs to be aware of both the potential risks of pharmacological treatment and the equally important risks of an untreated or undertreated disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, three guidelines offered explicit advice to use agents such as lorazepam, temazepam, oxazepam or brotizolam, which either undergo limited hepatic metabolism or have relatively shorter elimination half-lives to minimise theoretic fetal or lactational exposure.32,34,55”
From Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Approximately 20 to 40% of neonates who have been exposed to BZDs in utero during late pregnancy develop neonatal withdrawal, with symptoms including irritability, increased sedation, abnormal muscle tone, poor feeding, sleep problems, and mild respiratory distress.179–183”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [181]
In the citing paper
“BZD treatment specifications were provided more often in the context of perinatal/post-partum depressive disorders.32,34,55”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grote, N. K., Bridge, J. A., Gavin, A. R., Melville, J. L., Iyengar, S., & Katon, W. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.111 · Cited by 1,882 · cited 1×
“Interestingly, in five studies it was noted an increased risk of preterm birth exists for women with depression but without SSRI exposure during pregnancy [129,131,132,146,147].”
BackgroundACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052744 · Cited by 880
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · cited 1×
“Royal Australian and New Zealand College of Psychiatrists, 2015 [187] Australia and New Zealand Advise psychotherapy for new-onset depression”
BackgroundAlterations induced by gestational stress in brain morphology and behaviour of the offspring
Weinstock, M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00018-1 · Cited by 791
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Depression and anxiety in early pregnancy and risk for preeclampsia
Kurki, T. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00602-x · Cited by 690 · cited 2×
“It has been suggested that psychological conditions, such as stress, anxiety and depression [110,193], may trigger the pathogenic vascular processes that lead to this condition and need to be balanced against the effect induced by the pharmacological treatment.”
BackgroundThe comorbidity of depression and substance use disorders
Swendsen, J. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00026-4 · Cited by 632
Research works printed but not linked: 1
- Schloemp, 2006, Congenital malformations after antidepressant medication with paroxetine in early pregnancy?, Hum. Reprod., 21, i12
Cited by
Vigod, S. N., Frey, B. N., Clark, C. T., Grigoriadis, S., Barker, L. C., Brown, H. K., Charlebois, J., Dennis, C., Fairbrother, N., Green, S. M., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241303031 · Cited by 117
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Eleftheriou, G., Callegher, R. Z., Butera, R., Santis, M. D., Cavaliere, A. F., Vecchio, S., Lanzi, C., Davanzo, R., Mangili, G., Bondi, E., et al. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050551 · Cited by 36
Self-citationManagement of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide
Bergink, V., Suleiman, M., Hennen, M., & Robakis, T. K. (2025) · CNS Drugs · doi:10.1007/s40263-025-01202-7 · Cited by 14
Metadata
- Authors
- Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., Gallo, M., Balestrieri, M., & Albert, U.
- Affiliations
- Ospedale Papa Giovanni XXIII (IT)
- Italian Society of Psychiatry (SIP), piazza Santa Maria della Pietà 5, 00135 Rome, Italy
- Italian Society of Obstetrics and Gynecology (SIGO), via di Porta Pinciana 6, 00187 Rome, Italy
- Italian Society of Toxicology (SITOX), via Giovanni Pascoli 3, 20129 Milan, Italy
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ser.D Biella—Drug Addiction Service, 13875 Biella, Italy
- University of Udine (IT)
- University of Trieste (IT)
- Corresponding author
- Eleftheriou, Georgios
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2023-08-11
- Volume
- 20
- Issue
- 16
- Pages
- 6565
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC10454549
- OpenAlex
- W4385759437
- Cited by
- 17
- References
- 262
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 2
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- antidepressant use in pregnancy, fetal malformations, infant cognitive development, opioid use disorder in pregnancy, risk-benefit assessment, consensus recommendations, prenatal drug exposure, neonatal abstinence syndrome, maternal and fetal outcomes
- MeSH terms
- Clinical Decision-Making, Depressive Disorder, Female, Humans, Infant, Infant, Newborn, Pregnancy, Psychiatry, Anti-Anxiety Agents, Uncertainty, Pregnant People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders. https://app.cochat.ai/papers/10.3390/ijerph20166565
- The paper
- Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., Gallo, M., Balestrieri, M., & Albert, U. (2023). Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20166565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.